KANSAS, USA – October 29, 2026 – How does someone find the strength to remain grateful when life has brought unimaginable suffering? In Thank You God, For My Life, author Dianne Knaack
Portland-Based Experts on Brand and Marketing Strategy Will Help SenesTech Pursue E-Commerce and B2B Sales-Growth Opportunities. SURPRISE, Ariz. – October 28, 2026 – SenesTech, Inc. (NASDAQ: SNES), an innovator in rodent control,
New poetry collection builds on the message of You’re Not Alone and features ROOMS, a rock opera that transforms poetry into an immersive journey through music and storytelling WESTPORT, ONTARIO –
(Albany, New York) – October 29, 2026: According to DelveInsight’s analysis, the global Non-Cystic Fibrosis Bronchiectasis pipeline comprises 15+ key companies actively developing 13+ therapeutic candidates. The assessment provides comprehensive
The Endometrial Cancer clinical trial analysis report delivers important insights into ongoing research on 55+ pipeline drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 29, 2026
(Albany, New York) – October 29, 2026: According to DelveInsight’s analysis, the global Becker Muscular Dystrophy pipeline comprises 8+ key companies actively developing 8+ therapeutic candidates. The assessment provides comprehensive
The Familial Adenomatous Polyposis market analysis report delivers important insights into ongoing research on pipeline Familial Adenomatous Polyposis drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October
The Pemphigus Vulgaris market analysis report delivers important insights into ongoing research on pipeline Pemphigus Vulgaris drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 29, 2026,
Shanghai, China – October 28, 2026 – Frost & Sullivan has conducted in-depth research on the synthetic biology industry and published the “2026 White Book on the Development of Synthetic Biology
(Albany, New York) – October 29, 2026: According to DelveInsight’s analysis, the global Type 2 Diabetes pipeline comprises 75+ key companies actively developing 80+ therapeutic candidates. The assessment provides comprehensive
